chromatography, liquid electrophoresis
.
"kit" methods
The measurement of glycosylated proteins in patients with diabetes mellitus is an important index of chronic metabolic control and has been proposed as a pathogenetic model for diabetic complications (1) (2) (3) . The reaction and kinetics of formation of glycosylated hemoglobin (hemoglobin A1, hemoglobin Ai, "fast hemoglobin"), the most commonly used index of chronic metabolic control, have been studied in detail (4) . The slow, irreversible, nonenzymic formation of the ketoamine, hemoglobin A1, proceeds through a labile aldimine or Schiff base (4) . The formation of the aldimine is reversible and 60-fold faster than the rate-limiting formation of the final product. Although the measurement of hemoglobin A1 reflects the mean blood glucose concentration integrated over the preceding two months, the inclusion of the labile fraction in the measurement reflects acute blood glucose fluctuations and detracts from the assay as an index of chronic metabolic control (5) (6) (7) . We have previously demonstrated that liquidchromatographic and electrophoretic methods of measuring glycosylated hemoglobin concentration do not distinguish between hemoglobin A1 and the labile fractions (7) . Therefore, elimination of the labile fraction is necessary to preserve the utility of the assay. Incubation of erythrocyte samples in isotonic saline (7, 8) is time consuming (5 h at 38 #{176}C or 14 h at room temperature) and can produce hemolysis. In this paper we present a chemical means of removing the labile glycosylated fraction that is fast and convenient, does not cause hemolysis, and does not interfere with the measurement of the ketoamine adduct. We also used a commercially available "minicolumn" assay for hemoglobin A1 (Quik-SEP; Isolab, Inc., Akron, OH 44321), according to the manufacturer's directions at 23 #{176}C. The principle of separation of the glycosylated from nonglycosylated hemoglobin fractions is the same as the HPLC method and relies on the charge difference between the glycosylated and nonglycosylated fractions. The coefficients of variation for each of the three assays are listed in Table 1 .
To prepare "artificially" glycosylated samples, whole blood from research volunteers with no history of diabetes was collected into EDTA-containing tubes. As published previously, increased concentrations of the labile glycosylated fraction were generated by incubating erythrocytes in 10 g/L glucose at 37 #{176}C for 3 h (7). After glucose incubation, the erythrocytes were centrifuged (1000 X g, 5 mm, 4 #{176}C) and the packed erythrocytes were either hemolyzed directly and assayed or (chemically treated). The saline-incubated and chemically treated samples were then centrifuged, and the erythrocytes hemolyzed and assayed.
A different means of hemolyzing the packed erythrocytes was used for each assay method. For the HPLC method, three volumes of tie-ionized water and then three volumes of toluene were vigorously mixed with the packed erythrocytes.
After the hemolysate was separated from glycolipids by centrifugation at 1000 x g (30 mm, 4 #{176}C) we diluted the hemolysate in 80 mmolfL phosphate buffer, pH 6.82 (prepared from NaH2PO4 and Na2HPO4), containing 16 mmol of KCN per liter, and assayed 10 zg of hemoglobin. Preparation of hemolysate for the electrophoretic method was according to the manufacturer's directions: add five volumes of hemolyzing buffer (saponin, 1 g/L in water) to the packed erythrocytes and assay 1 giL. Hemolysate for the minicolumn method was also prepared according to the manufacturer's directions; whole blood was mixed with four volumes of hemolyzing buffer (surfactant/water, 1/1000 by vol). To further examine the effect of semicarbazide/aniline treatment on the reduction of labile hemoglobin, packed erythrocytes (6 zL) obtained from a nondiabetic volunteer were incubated for 3 h at pH 7.0, 38 #{176}C with D-[1-'4C]glucose (specific activity 55.8 Ci/mol) and 4 iL of NaPO4 buffer, 10 mmol/L, to make an isotonic solution containing 16 g of '4C]glucose per liter. The ethanol/water solution was evaporated from the ['4C]glucose with a gentle nitrogen stream before making the isotonic solution. After incubation, 100 zL of phosphate-buffered saline (per liter, 10 mmol of NaPO4, 140 mmol of NaCL, pH 7) was added and the solution was centrifuged (1000 X g, 4 mm, 4 #{176}C). The supernatant liquid was aspirated, the erythrocytes were suspended in 100 ML of phosphate-buffered saline, and the erythrocyte suspension was divided into two equal aliquots. The erythrocytes were centrifuged again, and one aliquot of packed cells was immediately prepared for assay by electrophoresis.
The other auquot was chemically treated; then the erythrocytes were collected by centrifugation, hemolyzed, and assayed by electrophoresis. Equal amounts of hemoglobin (assessed by absorbance at 410 nm) from the untreated and semicarbazide/ aniline-treated aliquots were assayed. The incorporation of 14C]glucose into the hemoglobin fractions was determined counts on the gel were in the hemoglobin A1 peaks.
Patients' samples were whole blood collected with EDTA from 31 diabetic patients of the Diabetes Clinic of the Massachusetts General Hospital. Each sample was divided; onehalf was saline-incubated, the other half chemically treated.
Results

Incubation of erythrocytes in increasing concentrations
of glucose produced an increase in labile glycosylated hemoglobin proportional to the glucose concentration as previously demonstrated 
Discussion
The glycosylated hemoglobin assay is a reliable index of blood glucose concentrations integrated over the two months prior to the assay (7, 8) . Unfortunately, 'all of the assay methods except the colorimetric method of Fluckinger and Winterhalter (10) fail to distinguish the labile from stable products. Therefore, samples must be pretreated to preserve the utility of the assay as an index of chronic metabolic eontrol. The pretreatment method used in previous studies, incubation of erythrocytes in isotonic saline, is effective but time consuming and can lead to sample hemolysis and spurious results.
We eliminated the labile fraction by treating erythrocytes with semicarbazide and aniline, pH 5.0, for 30 mm at 38 #{176}C. Semicarbazide, present in molar excess of glucose, acts both as a glucose trap and, we believe, as a nucleophile in a transschiffinization reaction. Other a-effect amines such as hydr#{225}zine, hydroxylamine, and thiosemicarbazide, which form stable glucose imines, have a similar effect and can be used in this procedure.
Treatment of erythrocytes with semicarbazide alone, however, did not completely eliminate the labile fraction within a 30-mm incubation time. The aminolysis of amines reportedly is subject to general-base, specific-acid catalysis We used these known features of amine breakdown to develop the semicarbazide/aniline treatment. Specific-acid Catalysis is provided by lowering the pH of the pretreatment solution to pH 5.0. As shown in Figure 3 , increasing proton concentration increases the efficiency of our pretreatment procedure, providing evidence that specific-acid catalysis is involved in the aminolysis of hemoglobin-glucose imines. The use of pH below 5 should be avoided, however, as this leads to considerable hemolysis. The addition of aniline to pH 5 semicarbazide greatly increased the rate of removal of labile hemoglobin. An aniline dose-response curve in the presence of 36 mmol of semicarbazide per liter (data not shown) indicated that the effect occurred with as little as 3.6 mmol of aniline per liter and was maximum at 8 mmol of aniline per liter.
A growing body of evidence supports the hypothesis that the vascular complications of diabetes are a direct result of the chronic increase of blood glucose concentration. Excessive glycosylation of a variety of blood and membrane proteins in diabetes has been demonstrated, and it is likely that the same two-step reaction that forms hemoglobin A1 is involved. The rapid and reliable chemical means we have developed for removing the labile glycosylated hemoglobin will aid the further study of protein glycosylation as well as simplify and preserve the utility of the hemoglobin A1 assay in diabetes.
